The price-to-earnings ratio for Hims & Hers Health Inc (NYSE: HIMS) is above average at 64.98x. The 36-month beta value for HIMS is also noteworthy at 1.61. There are mixed opinions on the stock, with 4 analysts rating it as a “buy,” 2 rating it as “overweight,” 8 rating it as “hold,” and 1 rating it as “sell.”
The public float for HIMS is 182.04M, and at present, short sellers hold a 28.48% of that float. The average trading volume of HIMS on March 24, 2025 was 20.85M shares.
HIMS) stock’s latest price update
The stock price of Hims & Hers Health Inc (NYSE: HIMS) has surged by 5.72 when compared to previous closing price of 32.87, but the company has seen a 4.86% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2025-03-20 that Hims & Hers Health has become one of the most popular growth stocks in the market today. After sharing with my readers a bullish perspective on the stock at ~$6/share in 2023, I’m back to provide a unique perspective that sheds light on what the platform does. In short, I like to call Hims an “AI-orchestrated general physician at national scale,” and I’ll walk us through what that means today.
HIMS’s Market Performance
Hims & Hers Health Inc (HIMS) has seen a 4.86% rise in stock performance for the week, with a -47.67% decline in the past month and a 11.66% surge in the past quarter. The volatility ratio for the week is 9.68%, and the volatility levels for the past 30 days are at 12.35% for HIMS. The simple moving average for the past 20 days is -7.01% for HIMS’s stock, with a 34.62% simple moving average for the past 200 days.
Analysts’ Opinion of HIMS
Many brokerage firms have already submitted their reports for HIMS stocks, with Morgan Stanley repeating the rating for HIMS by listing it as a “Equal-Weight.” The predicted price for HIMS in the upcoming period, according to Morgan Stanley is $60 based on the research report published on February 18, 2025 of the current year 2025.
Citigroup, on the other hand, stated in their research note that they expect to see HIMS reach a price target of $25, previously predicting the price at $24. The rating they have provided for HIMS stocks is “Sell” according to the report published on January 10th, 2025.
BTIG Research gave a rating of “Buy” to HIMS, setting the target price at $35 in the report published on January 07th of the current year.
HIMS Trading at -9.69% from the 50-Day Moving Average
After a stumble in the market that brought HIMS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -52.38% of loss for the given period.
Volatility was left at 12.35%, however, over the last 30 days, the volatility rate increased by 9.68%, as shares sank -29.48% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +25.59% upper at present.
During the last 5 trading sessions, HIMS rose by +4.86%, which changed the moving average for the period of 200-days by +69.59% in comparison to the 20-day moving average, which settled at $37.37. In addition, Hims & Hers Health Inc saw 43.71% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at HIMS starting from Oluyemi Okupe, who proposed sale 69,442 shares at the price of $34.75 back on Mar 21 ’25. After this action, Oluyemi Okupe now owns shares of Hims & Hers Health Inc, valued at $2,413,110 using the latest closing price.
Carroll Patrick Harrison, the Chief Medical Officer of Hims & Hers Health Inc, sale 23,287 shares at $34.31 during a trade that took place back on Mar 18 ’25, which means that Carroll Patrick Harrison is holding 209,661 shares at $798,977 based on the most recent closing price.
Stock Fundamentals for HIMS
Current profitability levels for the company are sitting at:
- 0.04 for the present operating margin
- 0.77 for the gross margin
The net margin for Hims & Hers Health Inc stands at 0.09. The total capital return value is set at 0.13. Equity return is now at value 30.71, with 21.62 for asset returns.
Based on Hims & Hers Health Inc (HIMS), the company’s capital structure generated 0.02 points at debt to capital in total, while cash flow to debt ratio is standing at 22.13.
Currently, EBITDA for the company is 61.9 million with net debt to EBITDA at -2.87. When we switch over and look at the enterprise to sales, we see a ratio of 4.89. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.79.
Conclusion
In summary, Hims & Hers Health Inc (HIMS) has had a better performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
